BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS

Mackensen A, Koenecke C, Haanen J, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, Borchmann P, Wiegert E, Schulz C, Rengstl B, Preussner L, Tuereci O, Sahin U (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Journal for ImmunoTherapy of Cancer BioMed Central

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: A1008-A1008

Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER

DOI: 10.1136/jitc-2021-SITC2021.958

Authors with CRIS profile

Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

BioNTech / Biopharmaceutical New Technologies

Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE)

Germany (DE) Netherlands Cancer Institute (NKI)

Netherlands (NL) Bexon Clinical Consulting

United States (USA) (US) Universitätsklinikum Köln

Germany (DE) Universitätsklinikum Regensburg

Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School

Germany (DE)

How to cite

APA:

Mackensen, A., Koenecke, C., Haanen, J., Alsdorf, W., Desuki, A., Wagner-Drouet, E.,... Sahin, U. (2021). BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (pp. A1008-A1008). LONDON: BMJ PUBLISHING GROUP.

MLA:

Mackensen, Andreas, et al. "BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMJ PUBLISHING GROUP, 2021. A1008-A1008.

BibTeX: Download